Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report
Name of Journal: World Journal of Translational Medicine
ESPS Manuscript NO: 5829
Title: Nanotechnological approaches in diabetes treatment: A new horizon
Reviewer code: 02446586
Science editor: Song, Xiu-Xia
Date sent for review: 2013-10-14 17:49
Date reviewed: 2013-11-30 17:56

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[ ] Grade A (Excellent)	[ ] Grade A: Priority Publishing	Google Search:	[ ] Accept
[ ] Grade B (Very good)	[ ] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[ ] Grade C (Good)	[Y] Grade C: a great deal of language polishing	[ ] No records	[ ]Rejection
[Y] Grade D (Fair)	[ ] Grade D: rejected	BPG Search:	[ ] Minor revision
[ ] Grade E (Poor)		[ ] Existed	[Y] Major revision
		[ ] No records	

COMMENTS TO AUTHORS

Title: Whether it accurately reflects the major topic and contents of the study. Yes Abstract: Whether it gives a clear delineation of the research background, objectives, materials and methods, results (including important data) and conclusions. Whether the innovative and significant points conform to the background, objectives, materials and methods, results (including important data) and conclusions. it's no structured Long introduction !!! Materials and methods the way of search ,not clear ,during which time ? Results no result in this study Discussion no well organized its review article search for literature should be clear no conclusion seen clearly !!! References up-to-date and relevant CLASSIFICATION OF THE MANUSCRIPT D (Oramed Pharmaceuticals, Inc., based in Jerusalem and Israel), which is currently conducting Phase 2B clinical trials of its oral insulin capsule, ORMD-0801, on 30 company name should be mentioned A combination of insulin therapy and sulphonylurea is more effective than insulin alone in treating patients with type 2 diabetes after secondary failure to oral drugs, leading to better glucose profiles and/or decreased insulin needs. This is illogic ,no one use sulphonylurea with insulin after sulphonylurea failure .What is the reference LANGUAGE EVALUATION Grade C this was written for non-medical professional looks for these statements The onset of diabetes mellitus (DM) is marked initially by an impaired glucose tolerance (increase in blood sugar level) Diabetes can be categorized into two types: Type I and Type II. Type 1 diabetes, (insulin-dependent diabetes mellitus; IDDM) NIDDM patients need to follow a diet and exercise program to control their blood inhibiting the production and release of glucose from the liver, which means you need less insulin to transport sugar into your cells, or iii) blocking the action of stomach enzymes that break down carbohydrates or make tissues more sensitive to insulin. Further, it is dangerous in case of a mistake, most especially injecting 'too much'

insulin causing hypoglycemia, which causes a dangerous fall in blood glucose level threatening even life Several other formulations of insulin nanoparticles were also administered to check if they can render protection to the drug carried through stomach acids and are able.

Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report
Name of Journal: World Journal of Translational Medicine
ESPS Manuscript NO: 5829
Title: Nanotechnological approaches in diabetes treatment: A new horizon
Reviewer code: 02446617
Science editor: Song, Xiu-Xia
Date sent for review: 2013-10-14 17:49
Date reviewed: 2013-12-20 02:56

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[ ] Grade A (Excellent)	[Y] Grade A: Priority Publishing	Google Search:	[ ] Accept
[ ] Grade B (Very good)	[ ] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[Y] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	[ ]Rejection
[ ] Grade D (Fair)	[ ] Grade D: rejected	BPG Search:	[Y] Minor revision
[ ] Grade E (Poor)		[ ] Existed	[ ] Major revision
		[ ] No records	

COMMENTS TO AUTHORS

This manuscript (MS) provides an overview of therapies being used for the treatment of diabetes with an emphasis on nano-formulations and alternative medicine. The MS is clearly written, presenting a very general perspective of the use of nanotechnology for the treatment of diabetes. Below are some specific comments pertaining content and some minors comment on syntaxes. Comments: Insulin: The most prominent biological molecule associated with diabetes In the description of exogenous supplemental insulin and how it is classified according to onset, peak and duration, the author could include more specific examples of the different types of supplemental insulin available (i.e. Fast, intermediate, long-term acting). A figure showing activity profiles of the different types of supplemental insulin can help illustrate the point. Use of nano insulin in diabetes treatment On this part, the authors states that "…using nano-insulin, as an effective new anti-diabetic strategy that may target any of the several mechanisms that that are involve in the development of diabetes; these may be done by adopting the proper correctional measures to bring the regulatory events back to the right track. " I think the authors should provide specific examples of how the nano-insulin will target the mechanism(s) involved in development of diabetes. Also, what are the proper correctional measures and how are these measure determined? A specific example on this topic will help strengthen an otherwise vague statement. Figures Please review the figure index, some of the figures referenced in the text are not included in the MS. The authors make reference to figure 2 and 3 but there is only one figure and two tables included as part of the MS. Minor comments 1) In the section entitled "Insulin: The most prominent biological molecule associated with diabetes", second paragraph; first line, the use of the article "the" before "blood glucose" is not necessary. 2) Paragraph 5, line 2; the "Use of nano-insulin in diabetes

treatment", please paraphrase, the statement is not clear.